Sunesis Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

SNSS 3.23 -0.02 (-0.62%)
price chart
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Rises 8%
Sunesis Pharmaceuticals, Inc. (SNSS - Snapshot Report) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
Analyst Price Target Update on Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) shares are expected to touch $3.2 in the short term. This short term price target has been shared by 5 analysts.
Sunesis Pharmaceuticals Inc. (SNSS) is Trading Lower on Unusual Volume for ...  Equities.com
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Rises 8% - Tale of the Tape  Nasdaq
Wedbush Reaffirms Hold Rating for Sunesis Pharmaceuticals (SNSS)
Other equities research analysts have also recently issued reports about the stock. Analysts at Roth Capital raised their price target on shares of Sunesis Pharmaceuticals from $4.00 to $5.50 and gave the company a “buy” rating in a research note on ...
Active Stocks to Watch For: Baxter International, (NYSE:BAX), Sunesis ...
Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), declined -0.62% to $3.23, during its last trading session. Sunesis Pharmaceuticals, declared that Daniel Swisher, Chief Executive Officer of Sunesis, will present at the Cantor Fitzgerald Inaugural ...
Company Shares of Sunesis Pharmaceuticals, Inc. Rally 6.52%
Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) rose by 6.52% in the past week and 24.05% for the last 4 weeks.
Biotech Stocks for you to follow - Biogen Inc (NASDAQ:BIIB), Sunesis ...  Wall Street Observer
Investors Are Watching: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), CIM ...  Stock Transcript
Sunesis Pharmaceuticals Inc. (SNSS) is Trading Higher on Unusual Volume for ...
Sunesis Pharmaceuticals Inc. (SNSS) experienced unusually high volume on Jul. 01, as the stock gained 7.97% to a closing price of $3.25.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Analyst Rating Update
Sunesis Pharmaceuticals (NASDAQ:SNSS) has received a short term rating of buy from research analysts at Zacks with a rank of 2. The company has been rated an average of 2.43 by 7 Wall Street Analysts. 3 analysts have added the shares in their list of ...
Healthcare Sector Movers: Arena Pharmaceuticals, Inc. (ARNA), PDL ...  WallStreet Scope
Biotech Stocks Worth Chasing - XOMA Corp (NASDAQ:XOMA), bluebird bio Inc ...  Wall Street Observer
Stocks With Escalations - Natera, (NASDAQ:NTRA), Xoom Corporation ...
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.
Stock Technical Report on Sunesis Pharmaceuticals Inc (NASDAQ:SNSS)
Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) (TREND ANALYSIS) shares were traded with thin volume. The stock closed last trading session at $2.48, up by 6.44%, with a volume of 911,392 shares against an average volume for the last 3 months of ...
Stocks in News: Immunomedics Inc. (NASDAQ:IMMU), Sunesis Pharmaceuticals ...  Stock Transcript
Are Shorts Hedging Their Bets On Sunesis Pharmaceuticals, Inc. (SNSS)?
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) gapped higher this morning, last seen up 8.7% at $2.76, after the company announced positive new data from its Phase 3 trial for leukemia drugs vosaroxin and cytarabine.
Here's Why Roth Capital Raised Price Target for Sunesis Pharmaceuticals ...  Smarter Analyst
Here Is Why Sunesis Pharmaceuticals, Inc. Stock Surged 12%  Bidness ETC